Final Analysis of the Phase III CLL10 Study: FCR versus BR in Physically Fit Patients with Previously Untreated, Advanced CLL


Final Analysis of the Phase III CLL10 Study: FCR versus BR in Physically Fit Patients with Previously Untreated, Advanced CLL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (1/8/15)
Eichhorst B et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Proc ASH 2014;Abstract 19.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.